Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2（BCL-2）and has great potential in treating a variety of hematological tumors. In recent years, domestic and foreign scholars have tried to use venetoclax singal or in combination with some drugs to treat the patients with hematological tumors, including elderly acute myeloid leukemia（AML）patients un suitable for intensive chemotherapy, relapsed or refractory chronic lymphocytic leukemia（CLL）, Non-Hodgkin's lymphoma（NHL）and multiple myeloma（MM）patients, these studies have achieved good results．At the same time，some scholars found that the secondary drug-resistance occurred in some patients who continuous treated with Venetoclax, and explored the Venetoclax-resistant mechanism. In this review, the research advance of Venetoclax in hematological tumors and the mechanisms of drug resistance are summarized and discussed briefly.
题目: Venetoclax在血液肿瘤中的最新研究进展.
摘要: Venetoclax是抗凋亡蛋白B细胞淋巴瘤因子-2（BCL-2）的一种选择性小分子抑制剂，在治疗多种血液肿瘤方面具有巨大潜力。近年来，有国内外学者尝试将Venetoclax单药应用或联合用药治疗血液恶性肿瘤患者，包括不适合进行强化化疗的老年急性髓系白血病（AML）患者，复发或难治性的慢性淋巴细胞白血病（CLL）、非霍奇金淋巴瘤（NHL）和多发性骨髓瘤（MM）患者，这些研究均取得较好的疗效。与此同时，有学者发现部分持续服药患者对Venetoclax产生了继发性耐药并探讨了产生耐药的机制。本文就Venetoclax在血液恶性肿瘤中的最新研究进展及患者产生耐药性的机制作一综述。.